Press release
Immune Thrombocytopenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Immune Thrombocytopenia Pipeline. Dive into DelveInsight's comprehensive report today! @ Immune Thrombocytopenia Pipeline Outlook [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Immune Thrombocytopenia Pipeline Report
* On 22 August 2025, Memorial Sloan Kettering Cancer Center conducted a study is to see if the study drug, romiplostim, helps low platelet count caused by standard chemotherapy treatment for lymphoma. This study will also look at whether romiplostim can prevent the need for chemotherapy dose delays, chemotherapy dose reductions, and platelet transfusions. In addition, we will determine how safe it is to give romiplostim to people with lymphoma who have low platelet count from chemotherapy.
* On 19 August 2025, Kedrion S.p.A . organized a study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP.therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
* DelveInsight's Immune Thrombocytopenia pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Immune Thrombocytopenia treatment.
* The leading Immune Thrombocytopenia Companies such as Corcept Therapeutics, UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development and others.
* Promising Immune Thrombocytopenia Pipeline Therapies such as Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets, and others.
Stay ahead with the most recent pipeline outlook for Immune Thrombocytopenia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Immune Thrombocytopenia Treatment Drugs [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Immune Thrombocytopenia Emerging Drugs Profile
* Rozanolixizumab (UCB7665): UCB
Rozanolixizumab humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P). By blocking IgG recycling, this subcutaneously infused monoclonal antibody aims to improve the course of immunoglobulin G (IgG)-mediated autoimmune diseases by reducing pathogenic autoantibody levels. Rozanolixizumab, an investigational monoclonal antibody, was granted orphan drug designation for the treatment of ITP by the US Food and Drug Administration on 30 April 2018 and by the European Commission on 11 January 2019. The drug is in Phase III clinical studies for the treatment of idiopathic thrombocytopenic purpura, myasthenia gravis and in Phase II clinical studies for chronic inflammatory demyelinating polyradiculoneuropathy and encephalitis.
* Efgartigimod: arGEN-X
Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. The drug is in registration phase for myasthenia gravis and in Phase III clinical studies for Primary Immune Thrombocytopenia (ITP), chronic inflammatory demyelinating polyradiculoneuropathy, and Pemphigus vulgaris.
The Immune Thrombocytopenia Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Immune Thrombocytopenia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Immune Thrombocytopenia Treatment.
* Immune Thrombocytopenia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Immune Thrombocytopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Immune Thrombocytopenia market
Explore groundbreaking therapies and clinical trials in the Immune Thrombocytopenia Pipeline. Access DelveInsight's detailed report now! @ New Immune Thrombocytopenia Drugs [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Immune Thrombocytopenia Companies
Corcept Therapeutics, UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development and others.
Immune thrombocytopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
Immune Thrombocytopenia Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Immune Thrombocytopenia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Immune Thrombocytopenia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Immune Thrombocytopenia Pipeline Report
* Coverage- Global
* Immune Thrombocytopenia Companies- Corcept Therapeutics, UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development and others.
* Immune Thrombocytopenia Pipeline Therapies- Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets, and others.
* Immune Thrombocytopenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Immune Thrombocytopenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Immune Thrombocytopenia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Immune Thrombocytopenia Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Immune thrombocytopenia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Immune thrombocytopenia - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Rozanolixizumab (UCB7665): UCB
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical/Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Immune thrombocytopenia Key Companies
* Immune thrombocytopenia Key Products
* Immune thrombocytopenia- Unmet Needs
* Immune thrombocytopenia- Market Drivers and Barriers
* Immune thrombocytopenia- Future Perspectives and Conclusion
* Immune thrombocytopenia Analyst Views
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=immune-thrombocytopenia-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immune Thrombocytopenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4158912 • Views: …
More Releases from ABNewswire
SERM Market Outlook 2034: Clinical Trials, FDA Approvals, Market Size, Therapies …
The Selective Estrogen Receptor Modulators (SERMs) market is anticipated to witness significant expansion in the coming years, fueled by the increasing prevalence of cancer, heightened awareness of SERM therapies, and a growing pipeline of candidates in clinical trials and regulatory review across multiple companies.
SERMs Market Summary
The Selective Estrogen Receptor Modulators (SERMs) market is expected to witness significant growth in the coming years, fueled by the increasing incidence of cancer, rising…
Hepatic Tumor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Appr …
DelveInsight's, "Hepatic Tumor Pipeline Insight 2025"report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Hepatic Tumor pipeline landscape. It covers the Hepatic Tumor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatic Tumor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options…
Advanced Ovarian Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA …
DelveInsight's, "Advanced Ovarian Cancer Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the Advanced Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Ovarian Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's…
Acute Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, …
DelveInsight's, "Acute Myeloid Leukemia Pipeline Insight" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
More Releases for Immune
Immune Probiotic Supplement Market Reviews: What Works Best for Gut and Immune S …
The Global Immune Probiotic Supplement Market reached US$ 68.73 Billion in 2024 and is projected to witness lucrative growth by reaching up to US$ 133.08 Billion by 2032. The Global Immune Probiotic Supplement Market is expected to exhibit a CAGR of 8.61% during the forecast period 2024-2032.
Immune Probiotic Supplement Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges.…
Decoding the Immune System: Immune Repertoire Sequencing Market Unleashes Insigh …
The Immune Repertoire Sequencing Market is likely to grow voraciously, i.e. at a CAGR of 7.3% between 2018-2026. Augmented and virtual reality are abreast with advanced technologies on a significant count. VR and AR do have loads of potential for offering in the healthcare vertical. The application areas include surgery and training simulation, and patients care and treatment.
Persistence Market Research (PMR) delivers the key insights on the immune repertoire sequencing…
Immune health supplement Market - Guardian of health: Supporting immune strength …
Newark, New Castle, USA: The "Immune health supplement Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Immune health supplement Market: https://www.growthplusreports.com/report/immune-health-supplement-market/7978
This latest report researches the industry structure,…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an…
Immune Health Supplements: Best Way to Boost Your Immune System
ResearchMoz include new market research report "Global Immune Health Supplements Market Research Report 2019" to its huge collection of research reports.
Immune Health Supplements refer to the product which could improve human immune health.
The global Immune Health Supplements market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
Learn more Through Sample Report…
